December 2016

Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to VTS-270, the company’s investigational drug for children with Niemann-Pick Type C1 disease (NPC). NPC is a progressive, irreversible, chronically debilitating – and ultimately lethal – genetic disease.

SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID and RealSeq) and European patent protection for its therapeutic short synthetic hairpin RNA (sshRNA) agents.

MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Tadalafil PharmFilm for the treatment of erectile dysfunction.

Merck  known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of therapy.

Indegene, a global healthcare solutions provider, announced the acquisition of The Encima Group - a pioneer in life science omnichannel marketing automation and analytics and partner to some of the world's largest pharmaceutical organizations. The Delaware Corporation was featured for the 4th consecutive year in the prestigious Inc. 5000 list of fastest-growing private companies in the United States.